Aurobindo Pharma Q1 PAT may dip 103% at Rs 4cr: P Lilladher
Prabhudas Lilladher expects Aurobindo Pharma to report a 96.1 percent degrowth quarter-on-quarter (fall of 103.3 percent year-on-year) in net profit at Rs 4.2 crore.
August 08, 2013 / 19:33 IST
Prabhudas Lilladher has come out with its first quarter (April-June) earnings estimates for the pharmaceutical sector. The brokerage house expects Aurobindo Pharma to report a 96.1 percent degrowth quarter-on-quarter (fall of 103.3 percent year-on-year) in net profit at Rs 4.2 crore.
Revenues are expected to increase by 9 percent Q-o-Q (up 41.3 percent Y-o-Y) to Rs 1,692.5 crore, according to Prabhudas Lilladher.Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to rise by 23.3 percent Q-o-Q (up 123.4 percent Y-o-Y) to Rs 274.3 crore.EBITDA margin or operating profit margin is likely to be at 16.2 percent in June quarter as against 14.3 percent in March quarter and 10.3 percent in a year ago period.Prabhudas Lilladher report on Aurobindo PharmaWe expect Aurobindo Pharma’s Q1FY14E revenue to grow at 40 percent Y-o-Y to INR 17 billion led by US generics and formulation growth. US sales growth to be bnenefitted from strong flow of approvals and favourable currency.With launches of valuable generics and increasing presence of injectables, the company to increase EBITDA margin by 200bps sequentially to 16 percent in Q1FY14E. Aurobindo's high foreign debt and working capital cycle remains to be strong hangover. With strong USD appreciation, We expect INR 1.5 billion forex loss in Q1FY14E. Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
